Cardiology

Jeff Meeusen, Ph.D., Co-Director of Cardiovascular Laboratory Medicine, recently had his paper, “Plasma Ceramides—A Novel Predictor of Major Adverse Cardiovascular Events after Coronary Angiography” accepted by the peer-reviewed journal Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB), part of the American Heart Association’s group of journals.

By Gina Chiri-Osmond • June 19, 2018

This "Specialty Testing" webinar will discuss what ceramides are and how they link to atherosclerosis and cardiovascular disease processes.

By MCL Education • April 25, 2018

In this month’s “Hot Topic,” Robin Patel, M.D., will review the laboratory methods used to diagnose infectious endocarditis. Specifically, she’ll discuss the role of blood cultures, nucleic acid amplification tests, histopathology, and recently, broad-range bacterial sequencing, and how these methods can assist in the diagnosis of this disease.

By Robin Patel, M.D. • April 2, 2018

At the annual meeting of the Association for Molecular Pathology this past November, Joseph Maleszewski, M.D., a cardiovascular pathologist and Professor of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota, presented about phenotypes and genotypes in the understanding and diagnosis of cardiovascular disease. He spoke with CAP Today further about gene testing in cardiomyopathy analysis.

By Kelley Luedke • March 19, 2018

Allan Jaffe, M.D., Consultant and Chair of Mayo Clinic’s Division of Clinical Core Laboratory Services, with a joint appointment in the Division of Cardiovascular Diseases, participated in a U.S. Food and Drug Administration meeting about the future of cardiac troponin testing.

By Kelley Luedke • March 13, 2018

This week’s Research Roundup highlights cardiovascular concerns in BRCA1 and BRCA2 mutation carriers.

By Kelley Luedke • March 12, 2018

Jeff Meeusen, Ph.D., Co-Director of Cardiovascular Laboratory Medicine in the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota, provides a clinical update on ceramides.

By Jeff Meeusen, Ph.D. • March 9, 2018

With more than 70,000 uses worldwide and policy endorsements for its use (JAMA Article), the Mayo Clinic Statin Choice Decision-Aid tool is helping patients and their clinicians have meaningful conversations about whether or not to use statins to reduce cardiovascular risk.

By Mayo Clinic Laboratories • January 25, 2018

Jeff Meeusen, Ph.D., a clinical chemist and Co-Director of Cardiovascular Laboratory Medicine at Mayo Clinic in Rochester, recently authored an article in Clinical Laboratory News that discusses patient fasting in lipid testing. While lipids measured on fasting samples have always been the status quo, the rules might be about to change.

By Kelley Luedke • January 22, 2018

High-sensitivity cardiac troponin levels are strongly associated with the risk for incident heart failure. Allan Jaffe, M.D., Consultant and Chair of Mayo Clinic’s Division of Clinical Core Laboratory Services, with a joint appointment in the Division of Cardiovascular Diseases, weighs in on the topic.

By Kelley Luedke • January 15, 2018

This week’s Research Roundup highlights how cardiac troponin is released from injured myocardium.

By Kelley Luedke • January 8, 2018

Allan Jaffe, M.D., Consultant and Chair of Mayo Clinic’s Division of Clinical Core Laboratory Services, with a joint appointment in the Division of Cardiovascular Diseases, spoke with CAP Today about what a new higher-sensitivity cardiac troponin assay means from a pathology and cardiology perspective.

By Kelley Luedke • December 27, 2017

This week’s Research Roundup highlights global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction.

By Kelley Luedke • December 25, 2017